- Login
- Register & Subscribe
- Language: EN FR DE
Sunday 15 August 2010
H. Lundbeck A/S said its profit before interest and tax (EBIT) increased by 30% to DKK 936 million (€125.6 million) in the 2010 second quarter on revenue of DKK 3.8 billion, up by 6.8%. It expects revenue of DKK 14.3 to 14.8 billion for the year.
Country: Denmark
Sunday 15 August 2010
Pronova BioPharma ASA, the Norwegian producer of omega-3 derived prescription products, posted a 2.6% decline in revenue in the second 2010 quarter to NOK 443.6 million (€55.9 million) and a 59% drop in net profit to NOK 51.7 million.
Country: Norway
Friday 13 August 2010
Two new approaches for treating Alzheimer’s disease have recently been disclosed. In separate announcements, a privately-owned company in Canada and researchers in Germany have put forward different approaches for disease-modifying therapies.
Country: Germany
Friday 13 August 2010
Algeta ASA is increasing manufacturing capacity for its lead product, a radiopharmaceutical, as recruitment continues in a pivotal Phase 3 trial of the product in patients with bone metastases arising from hormone-refractory prostate cancer.
Country: Norway
Thursday 12 August 2010
Evotec AG has reported a small operating profit for the 2010 first half – the first in its 17-year history. The profit, amounting to €0.3 million compared with a year-earlier loss of €29.1 million, comes a little more than a year into a major restructuring programme.
Country: Germany
Wednesday 11 August 2010
4SC AG expects to report data for its lead investigational compound, vidofludimus, in separate Phase 2 studies in inflammatory bowel disease and rheumatoid arthritis by the end of 2010. On 30 June, the German company had cash of €26.5 million.
Country: Germany
Wednesday 11 August 2010
Active Biotech AB, a listed Swedish drug development company focused on manipulating the immune system to treat major diseases, said its net loss for the first half of 2010 narrowed to SEK 108.1 million from SEK 118.6 million a year earlier.
Country: Sweden
Tuesday 10 August 2010
BioAlliance Pharma SA posted record revenue of €15.2 million in the 2010 second quarter in what was an illustration of how the fortunes of a small European company can be transformed by a single regulatory approval in the US.
Country: France
Tuesday 10 August 2010
Boehringer Ingelheim GmbH, reported a 2.8% decline in sales in the first half of 2010, mainly due to generic competition in the US. But it said new product sales would help it achieve a high, single-digit increase in 2011.
Country: Germany
Monday 9 August 2010
The safety and efficacy of the monoclonal antibody, ofatumumab, in the treatment of patients with refractory chronic lymphocytic leukaemia has been demonstrated in a pivotal clinical trial, according to its developers.
Country: Denmark
Tuesday September 7 2010
Friday September 3 2010
Friday August 20 2010
Friday August 20 2010
Thursday August 19 2010